Outset Medical, Inc. Stock Price, News & Analysis

Outset Medical (NASDAQ:OM) has announced a strategic collaboration with Northwest Kidney Centers to expand access to home hemodialysis using the Tablo® Hemodialysis System. Northwest Kidney Centers, pioneer of home hemodialysis programs, will integrate Tablo into their network where currently 20% of patients dialyze at home.

The Tablo system offers significant advantages, operating with standard tap water and electrical outlets, featuring a touchscreen interface and cloud connectivity. The collaboration aims to enhance patient care through Northwest Kidney Centers' comprehensive support system, including personalized training and 24/7 nursing access.

Outset Medical (NASDAQ: OM), a medical technology company focused on revolutionizing dialysis through innovative technology, has announced its participation in the upcoming 23rd Annual Morgan Stanley Global Healthcare Conference. The company's management will deliver their presentation on September 10, 2025, at 7:00 AM ET.

Investors and interested parties can access both the live presentation and archived webcast through the investor relations section of Outset Medical's website at investors.outsetmedical.com.

Outset Medical (Nasdaq: OM) reported strong Q2 2025 financial results, with net revenue reaching $31.4 million, up 15% year-over-year. The company's performance was driven by a 25% increase in Tablo console revenue and 11% growth in recurring revenue to $22.5 million.

Key highlights include improved gross margin of 37.8% (38.4% non-GAAP), a 30% reduction in operating expenses, and 60% lower cash usage compared to the previous year. The company secured a significant enterprise agreement providing Tablo access to over 100 facilities, expanding its presence to more than 900 acute and sub-acute sites in the U.S.

Following these results, Outset Medical raised its 2025 revenue guidance to $122-126 million from $115-125 million, maintaining expectations for high-30% non-GAAP gross margin and cash usage below $50 million for the year.

Outset Medical (Nasdaq: OM) has appointed Brittni McGill as its first Chief Nursing Officer, marking a significant addition to its executive team. McGill brings 18 years of nursing and hospital executive experience, previously managing over 1,400 employees at a 350-bed hospital.

In her prior role, McGill demonstrated notable success implementing Outset's Tablo system, achieving a 98% successful treatment rate and reducing central line blood stream infections by 75%. As CNO, she will lead clinical education and support programs for the dialysis nursing community, focusing on strategic outreach and clinical program innovation.

Outset Medical (Nasdaq: OM), a medical technology company focused on revolutionizing dialysis technology, has scheduled its Q2 2025 financial results announcement for August 6, 2025 after market close.

The company will host a conference call at 2:00 PM PT (5:00 PM ET) on the same day, featuring Chair and CEO Leslie Trigg and CFO Renee Gaeta. Participants can register online to receive dial-in details, and a webcast will be available on the company's investor relations website.

Outset Medical (Nasdaq: OM), a medical technology company focused on revolutionizing dialysis through innovative technology, has announced its participation in the Goldman Sachs 46th Annual Global Healthcare Conference. The company's management will deliver a presentation on Wednesday, June 11, 2025, at 11:20 a.m. Eastern time. Investors and interested parties can access both the live presentation and archived webcast through the company's investor relations website at investors.outsetmedical.com.

Outset Medical has appointed Renee Gaeta as its new Chief Financial Officer, effective immediately. Gaeta, who will oversee Finance, IT, and HR, succeeds Nabeel Ahmed. She previously served as CFO at Shockwave Medical until its $13B acquisition by Johnson & Johnson in 2024, and held CFO positions at Eko Health and Establishment Labs. The company reaffirmed its 2025 financial guidance, projecting revenue between $115M-$125M and non-GAAP gross margin in the high-30% range. Gaeta brings significant experience from publicly traded medical device companies, both as CFO and board member, including roles at Candel Therapeutics and SeaSpine Holdings. Outset Medical, a medical technology company, focuses on reducing dialysis cost and complexity through its Tablo technology.

Outset Medical (Nasdaq: OM) has appointed healthcare industry veteran Kevin O'Boyle to its Board of Directors and as chair of its Audit Committee, replacing Dale E. Jones who has stepped down. O'Boyle brings over 20 years of healthcare leadership experience, having served as CFO of several public companies and as a board director for 6 public medical device companies.

O'Boyle's extensive board experience includes positions at Nevro Corp., GenMark Diagnostics (as Chairman), Sientra, Wright Medical Group, Zeltiq Aesthetics, and Durata Therapeutics. He previously served as CFO of Advanced Biohealing and NuVasive, and currently serves on the board of Carlsmed, a private spine surgery solutions company.

Outset Medical (Nasdaq: OM), a medical technology company focused on revolutionizing dialysis through innovative technology, has announced its upcoming participation in the RBC Capital Markets Global Health Care conference. The company's management team will present on Tuesday, May 20, 2025, at 10:30 a.m. Eastern time. Investors and interested parties can access both the live and archived webcast of the presentation through the company's investor relations website at investors.outsetmedical.com.